Hepacivirus hominis Genome sequencing. Hepacivirus hominis

In 2016, Medecins Sans Frontieres (MSF) conducted in Cambodia a project aiming at screening and treating patients infected with Hepatitis C virus (HCV) with a regimen of Sofosbuvir and Daclatasvir (SOF+DCV). Despite a high rate (95%) of sustainable viral response 12 weeks after the end of treatment (SVR12), a few treated patients had experienced treatment failure. Using high throughput sequencing, we explored if genomic variations at the consensus level or in the intra-host diversity could cause treatment failure for selected patients infected with HCV genotype 6 (GT6). We provide here the new complete genomes of HCV GT6.